Offering a variety of enhanced features for image optimization and improved workflow efficiencies, the Sierra NMUS1 device reportedly includes the first software specifically designed for neuromuscular ultrasound applications.
Providing an array of benefits to bolster image quality and workflow efficiencies, the newly launched Sierra NMUS1™ combines neuromuscular ultrasound imaging with electrodiagnostic testing capabilities.
Featuring software specifically tailored to neuromuscular ultrasound, the Sierra NMUS1 device (Cadwell Industries) enables clinicians to access improved image quality through edge enhancement, advanced speckle reduction and spatial compounding, according to the company.
Cadwell Industries said the Sierra NMUS1 device offers three probes, a C-5-2 Curvilinear Probe, an L14-4 Linear Probe, and an HL18-4 Linear Hockey Stick Probe, that facilitate needle visualization and enhanced image quality. The neuromuscular ultrasound device also includes upgraded Sierra® 4 software with advanced artifact reduction and trace resolution, according to Cadwell Industries.
Through the Sierra 4 software, the Sierra NMUS1 device integrates electromyography (EMG) and nerve conduction studies (NCS). Other efficiencies of the Sierra NMUS1 system include automated labeling of images and results, easy measurement and annotation of images; and report generation that allows clinicians to document electrodiagnostic and imaging findings in one report, according to Cadwell Industries.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.